Strainprint™ Closes USD $3 Million (Cdn.$3.8M) Series A Funding
TORONTO, May 8, 2018 /PRNewswire/ – StrainprintTM Technologies — the leader in cannabis data and analytics is pleased to announce the closing of a USD $3 Million (Cdn.$3.8 Million) non-brokered, Series A private placement. The round was led by strategic industry investor, Cesare Fazari, Chairman of Molecular Science Corp and seed investor of leading cannabis companies, Ample Organics and Hydropothecary. Mr. Fazari […]
Strainprint Featured in Direct Cannabis Network: Strainprint ™ App,Tracking Your Cannabis Intake
Whether you are a medical cannabis patient or a recreational user, tracking your cannabis consumption habits are not only essential but also largely beneficial. Some people find it helpful to chronical their treatment journey in a paper-based journal but often find it inconvenient to capture each interaction and thus have an inaccurate record of […]
Blyss Cloud – Why We Love The Strainprint Marijuana App
Recently, the Strainprint App was featured on Blyss Cloud. Read all about why they love the Strainprint App!
Strainprint Launches Custom App Version For Canna Farms
Strainprint™ — the leader in cannabis data collection and strain efficacy reporting — is pleased to announce the release of the Canna Farms OEM version of the Strainprint mobile App. The newest custom-branded version of the Strainprint App is available exclusively for Canna Farms customers through a unique activation code.
Weedbox – Wanna Smoke More of the Right Weed?
Weedbox – Wanna Smoke More of the Right Weed? There’s An App for That! Recently, Strainprint was featured on Weedbox. Stephanie Karasick, Founder of Strainprint was interviewed about the app. Read her full interview and learn all about Strainprint below! View Article
Investing News Network: Changing the Limitations of Cannabis Research
On August 30th, 2017 Strainprint was featured on the Investing News Network. Our President, Dave Berg spoke to the Investing News Network about Strainprint and how we’re working to change the limitations of Medical Cannabis Research.